VivoCAR™ Anti-VEGFR-2 (1121) CAR mRNA-tLNP, T Cell Targeting (XS-0126-YX230)

Name: VivoCAR™ Anti-VEGFR-2 (1121) CAR mRNA-tLNP, T Cell Targeting
SKU: XS-0126-YX230
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

VivoCAR™ Anti-VEGFR-2 (1121) CAR mRNA-tLNP, T Cell Targeting targets Vascular Endothelial Growth Factor Receptor 2, a key mediator of tumor angiogenesis, using the 1121 clone. This product features a modular tLNP architecture for conjugation with Anti-CD3, CD8, CD4, CD7, CD5, or CD2 antibodies, enabling the precise redirection of CAR mRNA to specific systemic T-cell subsets. Its application is vital for researchers exploring the disruption of the tumor vasculature. The significance of the mRNA-tLNP system lies in its transient expression profile, providing a potent but self-limiting cytotoxic window that prevents permanent damage to normal endothelial networks.

Add to Cart

CAR Information

Target Species
Human

Clone
1121

Host
Human

CAR Construction
CD28-41BB-CD3z

CAR Generation
Third

CAR Signaling Description
This CAR construct features a CD28-4-1BB-CD3ζ signaling cassette. The design integrates a CD28 co-stimulatory domain to support strong initial T-cell activation, paired with a 4-1BB domain to promote long-term persistence, metabolic fitness, and resistance to exhaustion. The intracellular CD3ζ chain delivers the primary T-cell receptor signal, initiating robust effector functions such as rapid cytokine release (e.g., IFN-γ) upon target engagement.

CAR mRNA Properties

Cap
Cap 1

PolyA
Segmented PolyA

Product Type
CAR mRNA LNP

Lipid Mixture
Utilizes a proprietary lipid platform composed of ionizable lipid, cholesterol, helper phospholipid, and PEG-lipid.

Concentration
Lot specific

Buffer
The formulation is buffered in either Phosphate-Buffered Saline (PBS) or a citrate buffer containing 10% sucrose to maintain lipid nanoparticle stability and prevent aggregation during freeze-thaw cycles.

Storage
Maintain at -80°C. Avoid repeated freeze-thaw cycles to preserve mRNA integrity and LNP size distribution.

Handling
Thaw slowly on ice prior to use. Avoid vigorous vortexing; gently invert the vial to mix in order to preserve LNP integrity.

mRNA Quality Control

OD260/280
PASS

Agarose Gel Mobility
PASS

IVT Vector Sequencing
PASS

IVT Vector Enzyme Digestion
PASS

mRNA Transfection Efficiency
PASS

CAR Expression after mRNA Transfection
PASS

Target Information

Target
VEGFR-2

Gene Name
VEGFR-2, VEGFR

Introduction
VEGFR-2 is the primary mediator of VEGF-induced pro-angiogenic signaling, predominantly overexpressed on the vascular endothelial cells of solid tumors. In CAR-T therapy, targeting VEGFR-2 is a strategic approach to "starve" the tumor by disrupting its essential blood supply. Unlike direct tumor targeting, VEGFR-2 directed CAR-T cells collapse the supportive stroma, overcoming physical barriers like high interstitial pressure and facilitating broader immune infiltration into the tumor core.

Related Diseases
Various Solid Tumors (especially highly vascularized ones like Renal Cell Carcinoma, Hepatocellular Carcinoma, Glioblastoma, and Melanoma)

Gene ID
3791

UniProt ID
P35968

Sub CAT.	Product Name	T Cell Targeting	Ligand Type	Targeting Specificity	Conjugation Density	in vivo Stability
XS-0126-YX230-1	VivoCAR™ aCD7/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD7	Anti-CD7 antibody	Broadly targets the CD7 antigen expressed on the majority of peripheral T cells and Natural Killer (NK) cells. Leveraging CD7’s rapid receptor-mediated internalization kinetics, this ligand achieves the highest mRNA delivery efficiency among T-cell targets, facilitating potent in vivo CAR engineering even at lower lipid doses.	Optimized to exploit the high-turnover rate of the CD7 receptor. The conjugation density is precisely calibrated to trigger immediate "trigger-like" endocytosis upon binding, significantly outperforming other pan-T markers in cargo uptake while maintaining rigorous specificity within the PBMC microenvironment.	Engineered for high serum resilience and rapid escape from hepatic sequestration. Its superior internalization speed ensures that the mRNA-LNP complex is internalized by target T/NK cells shortly after contact, minimizing prolonged exposure to extracellular nucleases and systemic clearance mechanisms.
XS-0126-YX230-2	VivoCAR™ aCD3/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD3	Anti-CD3 antibody	Highly specific for the CD3 complex, facilitating pan-T cell mRNA delivery and enabling the simultaneous generation of helper (CD4+) and cytotoxic (CD8+) CAR-expressing cells.	Optimized to balance efficient cellular internalization with minimal off-target activation, achieving an ideal equilibrium for targeted delivery without inducing aberrant T-cell stimulation.	Ensures durable circulation and precise accumulation in lymphoid organs, particularly lymph nodes and the spleen, to facilitate effective engagement with resident T cells.
XS-0126-YX230-3	VivoCAR™ aCD2/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD2	Anti-CD2 antibody	Targets the CD2 (LFA-2) adhesion molecule, encompassing nearly all mature T cells and NK cells. By utilizing the natural adhesive properties of CD2, this ligand promotes the formation of a stable "immune synapse-like" interface between the LNP and the target cell, enhancing membrane proximity for cargo transfer.	Developed with a high-density conjugation strategy to capitalize on the high copy number of CD2 on the lymphocyte surface. While the endocytic rate is slower than CD7, the increased contact stability ensures robust total uptake and reduces non-specific interactions with off-target tissues like the liver or lungs.	Exhibits robust ligand stability and resistance to opsonization in the bloodstream. The antibody scaffold is modified to extend half-life, ensuring that the complexes remain bioactive until they achieve targeted infiltration into lymphoid organs and inflammatory tumor sites.
XS-0126-YX230-4	VivoCAR™ aCD5/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD5	Anti-CD5 antibody	Directs mRNA-LNP complexes to CD5+ populations, primarily targeting the vast majority of mature T cells (both helper and cytotoxic) to create a multi-lineage in vivo CAR response.	Fine-tuned to achieve an optimal balance between highly efficient mRNA delivery into T-cells and the prevention of fratricidal CAR-T cell activity.	Engineered for sustained circulatory persistence, enabling prolonged navigation and targeted infiltration of malignant T-cell niches.
XS-0126-YX230-5	VivoCAR™ aCD4/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD4	Anti-CD4 antibody	Exclusively targets the CD4+ helper T cell subset. This specificity is designed to generate CAR-expressing cells with long-lived memory characteristics and immunomodulatory functions, providing a supportive cytokine microenvironment for a sustained and coordinated anti-tumor response.	The ligand load is fine-tuned to balance binding avidity with the moderate internalization rate of the CD4 receptor. This ensures efficient entry without inducing excessive signaling that could lead to premature T-cell exhaustion or unintended phenotypic shifts during the transfection process.	Demonstrates exceptional structural integrity during systemic circulation. It exhibits a favorable pharmacokinetic profile that allows for prolonged persistence in the blood, ensuring precise homing and accumulation within the paracortical areas of lymph nodes where CD4+ cells are densely resident.
XS-0126-YX230-6	VivoCAR™ aCD8/tLNP-Anti-VEGFR-2 (1121) CAR mRNA	CD8	Anti-CD8 antibody	Highly specific for CD8+ T cells, enabling targeted mRNA delivery via antibody-receptor mediated endocytosis for in situ reprogramming.	The conjugation density of the CD8 antibody is optimized to ensure LNP internalization occurs specifically upon binding to the CD8 antigen, thereby preventing non-specific uptake by off-target cells such as hepatocytes or other hematopoietic lineages.	Exhibits high ligand stability in circulation, ensuring effective targeted accumulation in lymphoid organs such as the spleen and bone marrow.

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-VEGFR-2 (1121) CAR mRNA-tLNP, T Cell Targeting (XS-0126-YX230). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.